These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29061853)

  • 1. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
    Mihai C; Antic M; Dobrota R; Bonderman D; Chadha-Boreham H; Coghlan JG; Denton CP; Doelberg M; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Rosenberg DM; Seibold JR; Vonk MC; Distler O
    Ann Rheum Dis; 2018 Jan; 77(1):128-132. PubMed ID: 29061853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
    Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
    Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension].
    Wang H; Tian Z; Liu Y; Li M; Wang Q; Zeng X; Fang Q
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):390-3. PubMed ID: 25146407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China.
    Huang J; Li M; Tian Z; Hsieh E; Wang Q; Liu Y; Xu D; Hou Y; Zhao J; Guo X; Lai J; Hu C; Song N; Sun Q; Sun Q; Zhang F; Zhao Y; Zeng X
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-115-21. PubMed ID: 25372797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.
    Overbeek MJ; Groepenhoff H; Voskuyl AE; Smit EF; Peeters JW; Vonk-Noordegraaf A; Spreeuwenberg MD; Dijkmans BC; Boonstra A
    Respir Res; 2008 Oct; 9(1):68. PubMed ID: 18828919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.
    Ninagawa K; Kato M; Nakamura H; Abe N; Kono M; Fujieda Y; Oku K; Yasuda S; Ohira H; Tsujino I; Atsumi T
    Rheumatol Int; 2019 Nov; 39(11):1883-1887. PubMed ID: 31280357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
    Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
    Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and predictors of pulmonary artery hypertension in systemic sclerosis.
    Kumar U; Ramteke R; Yadav R; Ramam M; Handa R; Kumar A
    J Assoc Physicians India; 2008 Jun; 56():413-7. PubMed ID: 18822619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
    Hinchcliff M; Fischer A; Schiopu E; Steen VD;
    J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
    Hsu VM; Chung L; Hummers LK; Wigley F; Simms R; Bolster M; Silver R; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Alkassab F; Steen VD
    Semin Arthritis Rheum; 2014 Aug; 44(1):55-62. PubMed ID: 24709277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.
    Morrisroe K; Stevens W; Sahhar J; Rabusa C; Nikpour M; Proudman S;
    Arthritis Res Ther; 2017 Mar; 19(1):42. PubMed ID: 28270192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease.
    Fischer A; Misumi S; Curran-Everett D; Meehan RT; Ulrich SK; Swigris JJ; Frankel SK; Cosgrove GP; Lynch DA; Brown KK
    Chest; 2007 Apr; 131(4):988-92. PubMed ID: 17426200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of pulmonary arterial hypertension in scleroderma.
    Plastiras SC; Karadimitrakis SP; Kampolis C; Moutsopoulos HM; Tzelepis GE
    Semin Arthritis Rheum; 2007 Jun; 36(6):392-6. PubMed ID: 17204309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.